SELLAS Life Sciences
16 hedge funds and large institutions have $2.07M invested in SELLAS Life Sciences in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 13 closing their positions.
4,236% more call options, than puts
Call options by funds: $477K | Put options by funds: $11K
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
4% more capital invested
Capital invested by funds: $1.99M → $2.07M (+$84.2K)
0.19% more ownership
Funds ownership: 0.01% → 0.2% (+0.19%)
33% less funds holding
Funds holding: 24 → 16 (-8)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.27M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$318K |
| 3 |
Renaissance Technologies
New York
|
+$307K |
| 4 |
Morgan Stanley
New York
|
+$144K |
| 5 |
VF
Virtu Financial
New York
|
+$60.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CGA
Crescent Grove Advisors
Lake Forest,
Illinois
|
-$31K |
| 2 |
State Street
Boston,
Massachusetts
|
-$30K |
| 3 |
Goldman Sachs
New York
|
-$29K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$18K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$10K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AWM
26
Aevitas Wealth Management
Wellesley Hills,
Massachusetts
| – | +$285 | +1 | New |
|
27
Barclays
London,
United Kingdom
| – | +$285 | +1 | New |
|
|
LTFS
28
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | +$571 | +2 | +200% |
|
SLS Hedge Fund Activity: Q1 2018 in Review
16 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q1 2018, worth a combined $2.07M — up 4.2% from $1.99M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SLS and 5 opened new positions — a net loss of 8 holders — while 2 trimmed existing stakes and 7 added.
The largest buyer was Sabby Management, adding an estimated $1.27M. The largest seller was Crescent Grove Advisors, exiting entirely with an estimated $31K sold.
- 16 institutional investors held SELLAS Life Sciences (SLS) as of Q1 2018, down from 24 in Q4 2017.
- Funds reported $2.07M of SELLAS Life Sciences stock for Q1 2018, up 4.2% quarter-over-quarter.
- 5 funds opened new SELLAS Life Sciences positions in Q1 2018 and 13 closed out, a net change of -8 holders.
- The largest SELLAS Life Sciences buyer in Q1 2018 was Sabby Management, an estimated $1.27M added.
- The largest SELLAS Life Sciences seller in Q1 2018 was Crescent Grove Advisors, an estimated $31K sold.
Based on aggregated 13F filings for Q1 2018.